NCT00544804View on ClinicalTrials.gov

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Breast CancerMetastatic Cancer
Interventions
DRUG

lapatinib ditosylate

GENETIC

gene expression analysis

OTHER

diagnostic laboratory biomarker analysis

Trial Locations (1)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00544804 - Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 | Biotech Hunter | Biotech Hunter